A ngiogenesis is a hallmark of cancer. Growing tumors recruit networks of new vasculature to meet their increased demand for oxygen and nutrients, as well as for efficient removal of metabolic waste products.
its signaling cascade has been extensively studied, and VEGFA inhibitors, such as bevacizumab and other VEGFR2 inhibitors, have emerged as agents for antiangiogenesis therapy in cancer. 2, 4 Ramucirumab is an intravenously administered human monoclonal antibody (IgG1) that selectively binds the extracellular domain of VEGFR2, blocking access of VEGF ligand. 4 In mice, a murine VEGFR2 monoclonal antibody (DC101) was found to strongly inhibit tumor growth, 5 and ramucirumab has recently been found to have efficacy in gastric and gastroesophageal junction adenocarcinomas. 4 The most common adverse effects of ramucirumab (shared among all antiangiogenic agents) include hypertension due to a decrease in VEGF-dependent nitric oxide production and proteinuria due to an inhibition of VEGFdependent interactions between podocytes and the glomerular endothelium. 1, 4 With promising results in its phase 3 trials, ramucirumab gained approval from the US Food and Drug Administration in April 2014 for use in patients with advanced or metastatic gastric and gastroesophageal junction cancer with disease progression during or after pretreatment with platinumcontaining or fluoropyrimidine-containing chemotherapy. 4 On-IMPORTANCE Inhibition of angiogenesis is an effective anticancer strategy because neoplasms require a rich blood supply. Ramucirumab, approved by the US Food and Drug Administration in 2014 to treat gastric adenocarcinomas and non-small cell lung carcinomas, targets vascular endothelial growth factor 2 (VEGFR2). We identified a patient prescribed a regimen of irinotecan hydrochloride, cetuximab, and ramucirumab for metastatic rectal cancer (diagnosed in November 2013 and treated through early January 2015) who developed a new-onset, expanding vascular lesion on his right leg. Via exome sequencing, we found that the lesion contained a single somatic mutation in KDR (encodes VEGFR2), possibly in response to ramucirumab. Vascular tumors are not a known complication of antiangiogenic therapeutics. Report of a Case In early January 2015 after 2 cycles of the trial, he developed a single, well-defined, blanchable bright red plaque densely composed of telangiectasias on his lower right lateral shin, which grew to 4 cm ( Figure 1A ). There was no associated pain or pruritus. Histopathological analysis showed discrete clusters of small-caliber vessels, most resembling a tufted angioma ( Figure 1B and C) .
OBSERVATIONS
To determine the genetic basis of this new vascular tumor, we used paired whole-exome sequencing of affected tissue (labeled ANGIO100) and the patient's blood. After alignment of exome data to the Human Genome version 19 reference genome, tissue-specific somatic variants were annotated, and nonsynonymous mutations were filtered for variants absent in normal control data sets, including the Exome Aggregation Consortium, the 1000 Genomes Project, and the National Heart, Lung, and Blood Institute (eAppendix in the Supplement). Using a Fisher exact test to rank somatic variants with a genome-wide significance, we identified a list of candidate mutations that were subsequently viewed using a software program (Integrated Genomics Viewer; https://www.broadinstitute .org/igv/) to exclude mismapped reads. KDR (VEGFR2) c.C2312G, p.T771R was identified as the only somatic mutation from this analysis (Figure 2 and eTable and eFigure 1 in the Supplement). ExomeCNV 7 did not identify copy number variations or regions of loss of heterozygosity across the genome, implicating the identified KDR variant as the driver of the vascular lesion (eFigure 2 and eAppendix in the Supplement). We confirmed the KDR mutation via laser capture microdissection of the proliferating vessels and Sanger sequenc- Given the rapid appearance after the initiation of therapy and the time line of our patient's vascular lesion, we believe the mutation arose in response to the E7208 trial regimen. KDR p.T771R was previously identified in 4 patients with angiosarcoma 12 in conjunction with other mutations listed in the Catalogue of Somatic Mutations in Cancer (http://cancer .sanger.ac.uk/cosmic), and expression studies of angiosarcoma revealed upregulation of KDR, with approximately 10% of patients harboring KDR mutations. 13 In addition to p.T771R, p.N717V and p.A1065T were identified in other cases of angiosarcoma. 12, 13 In vitro studies have shown that these mutations lead to autophosphorylation of the KDR tyrosine kinase, suggesting that these variants are activating mutations.
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The mechanism of mutagenesis remains unclear. For vemurafenib-induced keratoacanthomas, activating HRAS mutations are postulated to have occurred before therapy, while on exposure to vemurafenib the inhibition of BRAF leads to transactivation of CRAF (OMIM 164760) and upregulated downstream MAPK (OMIM 610389) signaling.
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